Can a new drug shrink Hard-to-Treat solid tumors?

NCT ID NCT07718581

Not yet recruiting Disease control Sponsor: Hutchmed Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests an experimental drug called HMPL-A830 in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then testing that dose in more people to see if it can shrink tumors. The goal is to understand the drug's safety, how the body processes it, and whether it shows promise against cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called HMPL-A830
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is an early-phase trial, so the drug may not prove safe or effective. Side effects are unknown, and the small number of participants limits what can be concluded.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Cancer Hospital

    Beijing, China

    Contact

  • Hunan Cancer Hospital

    Changsha, China

    Contact

  • Jiangsu Province Hospital

    Nanjing, China

    Contact

  • Shandong Cancer Hospital

    Jinan, China

    Contact

  • Shanxi Provincial Cancer Hospitial

    Taiyuan, China

    Contact

  • The Sixth Affiliated Hospital,Sun Yat-sen University

    Guangzhou, China

    Contact

  • West China Hospital of Sichuan University

    Chengdu, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.